| Year |
Citation |
Score |
| 2013 |
Laheru D, Biedrzycki B, Jaffee EM. Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Methods in Molecular Biology (Clifton, N.J.). 980: 175-203. PMID 23359154 DOI: 10.1007/978-1-62703-287-2_9 |
0.507 |
|
| 2013 |
Ng J, Uram J, Onners B, Biedrzycki B, Sugar E, Solt S, Armstrong T, Le D, Zheng L, Schroeder J, Jaffee E, Laheru D. Abstract B27: IgE-independent hypersensitvity reactions are associated with prolonged survival in advanced pancreatic cancer patients receiving a GM-CSF cell-based vaccine plus cyclophosphamide (Cy) and cetuximab. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B27 |
0.477 |
|
| 2011 |
Biedrzycki BA. Factors and outcomes of decision making for cancer clinical trial participation. Oncology Nursing Forum. 38: 542-52. PMID 21875841 DOI: 10.1188/11.Onf.542-552 |
0.31 |
|
| 2011 |
Biedrzycki BA. Research information knowledge, perceived adequacy, and understanding in cancer clinical trial participants. Oncology Nursing Forum. 38: E291-6. PMID 21708524 DOI: 10.1188/11.Onf.E291-E296 |
0.351 |
|
| 2011 |
Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Annals of Surgery. 253: 328-35. PMID 21217520 DOI: 10.1097/Sla.0B013E3181Fd271C |
0.418 |
|
| 2010 |
Biedrzycki BA. Decision making for cancer clinical trial participation: a systematic review. Oncology Nursing Forum. 37: E387-99. PMID 21059572 DOI: 10.1188/10.Onf.E387-E399 |
0.315 |
|
| 2010 |
Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 338-47. PMID 20048335 DOI: 10.1158/1078-0432.Ccr-09-2046 |
0.393 |
|
| 2009 |
Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5911-8. PMID 19805669 DOI: 10.1200/Jco.2009.23.3494 |
0.467 |
|
| 2008 |
Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1455-63. PMID 18316569 DOI: 10.1158/1078-0432.Ccr-07-0371 |
0.413 |
|
| 2007 |
Laheru D, Yeo C, Biedrzycki B, Solt S, Lutz E, Onners B, Tartakovsky I, Herman J, Hruban R, Piantadosi S, Jaffee E. A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas Journal of Clinical Oncology. 25: 3010-3010. DOI: 10.1200/Jco.2007.25.18_Suppl.3010 |
0.505 |
|
| 2006 |
Biedrzycki BA. What if preventing cancer is as easy as being vaccinated? Ons News / Oncology Nursing Society. 21: 9-10. PMID 16929566 |
0.359 |
|
| 2006 |
Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3394-401. PMID 16740763 DOI: 10.1158/1078-0432.Ccr-06-0145 |
0.378 |
|
| 2006 |
Smith B, Kasamon YL, Miller CB, Chia C, Gocke C, Kowalski J, Tartakovsky I, Biedrzycki B, Jones RJ, Hege K, Levitsky HI. K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (PTS) with residual disease on imatinib mesylate (IM) Journal of Clinical Oncology. 24: 6509-6509. DOI: 10.1200/Jco.2006.24.18_Suppl.6509 |
0.432 |
|
| 2005 |
Laheru D, Biedrzycki B, Thomas AM, Jaffee EM. Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Methods in Molecular Medicine. 103: 299-327. PMID 15542914 DOI: 10.1385/1-59259-780-7:299 |
0.506 |
|
| 2005 |
Smith BD, Kasamon YL, Miller CB, Chia C, Murphy K, Kowalski J, Tartakovsky I, Biedrzycki B, Jones RJ, Hege K, Levitsky HI. K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM). Blood. 106: 2858-2858. DOI: 10.1182/Blood.V106.11.2858.2858 |
0.44 |
|
| 2005 |
Chia CY, Smith BD, Kasamon Y, Miller CB, Brummet ME, Bankova L, Kowalski J, Biedrzycki B, Hege K, Beck LA, Levitsky H. Characterization of Vaccine Site and Cellular Infiltrate in Subjects with Chronic Myeloid Leukemia (CML) Receiving K562/GM-CSF Vaccination in Combination with Imatinib Mesylate with or without Topical Imiquimod. Blood. 106: 2399-2399. DOI: 10.1182/Blood.V106.11.2399.2399 |
0.431 |
|
| 2004 |
Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis-Sproul J, Fetting J, Jaffee E, Onners B, Piantadosi S, Reilly RT, Stearns V, Tartakovsky I, Visvanathan K, Wolff A. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Human Gene Therapy. 15: 313-37. PMID 15018740 DOI: 10.1089/104303404322886165 |
0.34 |
|
| 2004 |
Borrello I, Biedrzycki B, Sheets N, George B, Racke F, Loper K, Noonan K, Donnelly A, Hege K, Levitski H. Autologous Tumor Combined with a GM-CSF-Secreting Cell Line Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma. Blood. 104: 440-440. DOI: 10.1182/Blood.V104.11.440.440 |
0.47 |
|
| 2001 |
Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O'Reilly S, Abrams RA, Pardoll DM, Cameron JL, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 145-56. PMID 11134207 DOI: 10.1200/Jco.2001.19.1.145 |
0.473 |
|
| Show low-probability matches. |